☰

Igor Vivanco, Ph.D. - Publications

Affiliations: 
2005 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Gutierrez-Prat N, Zuberer HL, Mangano L, Karimaddini Z, Wolf L, Tyanova S, Wellinger LC, Marbach D, Griesser V, Pettazzoni P, Bischoff JR, Rohle D, Palladino C, Vivanco I. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Life Science Alliance. 5. PMID 35580987 DOI: 10.26508/lsa.202101235  0.312
2021 Coleman N, Harbery A, Heuss S, Vivanco I, Popat S. Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 164: 56-68. PMID 35033939 DOI: 10.1016/j.lungcan.2021.12.016  0.345
2021 Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA. Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmacogenomics and Personalized Medicine. 14: 1517-1535. PMID 34858045 DOI: 10.2147/PGPM.S305068  0.447
2020 Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, Barker K, Urban Z, Thway K, Zeid R, Hallsworth A, Box G, Ebus ME, Licciardello MP, Sbirkov Y, ... ... Vivanco I, et al. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. The Journal of Clinical Investigation. PMID 33016930 DOI: 10.1172/JCI134132  0.34
2020 Lazaro G, Kostaras E, Vivanco I. Inhibitors in AKTion: ATP-competitive vs allosteric. Biochemical Society Transactions. PMID 32453400 DOI: 10.1042/Bst20190777  0.485
2020 Kostaras E, Kaserer T, Lazaro G, Heuss SF, Hussain A, Casado P, Hayes A, Yandim C, Palaskas N, Yu Y, Schwartz B, Raynaud F, Chung YL, Cutillas PR, Vivanco I. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. British Journal of Cancer. PMID 32439931 DOI: 10.1038/S41416-020-0889-4  0.464
2018 Stein S, Zhao R, Haeno H, Vivanco I, Michor F. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. Plos Computational Biology. 14: e1005924. PMID 29293494 DOI: 10.1371/Journal.Pcbi.1005924  0.444
2017 Oldrini B, Hsieh WY, Erdjument-Bromage H, Codega P, Carro MS, Curiel-García A, Campos C, Pourmaleki M, Grommes C, Vivanco I, Rohle D, Bielski CM, Taylor BS, Hollmann TJ, Rosenblum M, et al. EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nature Communications. 8: 2035. PMID 29229958 DOI: 10.1038/S41467-017-02185-W  0.504
2017 Hsieh W, Oldrini B, Erdjument-Bromage H, Codega P, Carro MS, Vivanco I, Rohle D, Campos C, Bielski C, Taylor B, Tempst P, Squatrito M, Mellinghoff IK. Abstract 1032: Identification of Ran binding protein 6 as a novel negative regulator of EGFR and candidate tumor suppressor in glioblastoma Cancer Research. 77: 1032-1032. DOI: 10.1158/1538-7445.Am2017-1032  0.383
2015 Tanos BE, Perez Bay AE, Salvarezza S, Vivanco I, Mellinghoff I, Osman M, Sacks DB, Rodriguez-Boulan E. IQGAP1 controls tight junction formation through differential regulation of claudin recruitment. Journal of Cell Science. 128: 853-62. PMID 25588839 DOI: 10.1242/Jcs.118703  0.312
2014 Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, Campos C, Mellinghoff IK. A kinase-independent function of AKT promotes cancer cell survival. Elife. 3. PMID 25551293 DOI: 10.7554/Elife.03751  0.547
2014 Vivanco I. Targeting molecular addictions in cancer. British Journal of Cancer. 111: 2033-8. PMID 25268375 DOI: 10.1038/Bjc.2014.461  0.462
2014 Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh W, Yannuzzi N, Campos C, Mellinghoff IK. Author response: A kinase-independent function of AKT promotes cancer cell survival Elife. DOI: 10.7554/Elife.03751.028  0.489
2012 Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular Systems Biology. 8: 589. PMID 22735335 DOI: 10.1038/Msb.2012.20  0.411
2012 Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery. 2: 458-71. PMID 22588883 DOI: 10.1158/2159-8290.Cd-11-0284  0.547
2010 Vivanco I, Mellinghoff IK. Epidermal growth factor receptor inhibitors in oncology. Current Opinion in Oncology. 22: 573-8. PMID 20739887 DOI: 10.1097/Cco.0B013E32833Edbdf  0.51
2010 Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 107: 6459-64. PMID 20308550 DOI: 10.1073/Pnas.0911188107  0.564
2010 Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics. 42: 77-82. PMID 19946270 DOI: 10.1038/Ng.491  0.37
2010 Peng L, Wu TT, Tchieu JH, Feng J, Brown HJ, Feng J, Li X, Qi J, Deng H, Vivanco I, Mellinghoff IK, Jamieson C, Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. The Journal of General Virology. 91: 463-9. PMID 19864499 DOI: 10.1099/Vir.0.015073-0  0.46
2009 Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. The Journal of Clinical Investigation. 119: 3000-10. PMID 19759520 DOI: 10.1172/Jci38746  0.513
2009 Meng S, Arbit T, Veeriah S, Mellinghoff IK, Fang F, Vivanco I, Rohle D, Chan TA. 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle (Georgetown, Tex.). 8: 2238-46. PMID 19502805 DOI: 10.4161/Cc.8.14.8998  0.336
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106  0.518
2007 Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/Pnas.0710052104  0.323
2007 Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Research. 67: 6083-91. PMID 17616663 DOI: 10.1158/0008-5472.Can-06-4202  0.542
2007 Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 11: 555-69. PMID 17560336 DOI: 10.1016/J.Ccr.2007.04.021  0.608
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485  0.638
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392  0.658
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918  0.636
2004 Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6: 517-27. PMID 15542435 DOI: 10.1016/J.Ccr.2004.09.031  0.657
2002 Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Molecular Endocrinology (Baltimore, Md.). 16: 2323-37. PMID 12351697 DOI: 10.1210/Me.2002-0004  0.344
2002 Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews. Cancer. 2: 489-501. PMID 12094235 DOI: 10.1038/Nrc839  0.633
1999 Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DEH. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors Proceedings of the National Academy of Sciences of the United States of America. 96: 14523-14528. PMID 10588738 DOI: 10.1073/Pnas.96.25.14523  0.359
Show low-probability matches.